The key catalyst is the OPERA-01 top-line data in Q1 2027. Monitor enrollment updates for OPERA-02 and any early efficacy signals from the upcoming SABCS presentations in December 2026.
Drugs in focus
OLMA drug pipeline →palazestrant
● Neutral Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If the OPERA-01 Phase 3 trial succeeds, palazestrant could potentially be filed for FDA approval in 2027, with a potential launch in 2028 at the earliest, assuming no regulatory delays.
- Next catalyst
- None dated
What to watchThe next hard catalyst is the SABCS 2026 presentation in December 2026, where Olema will show combination data for palazestrant with ribociclib and for its KAT6 inhibitor OP-3136. The truly binary event is the OPERA-01 Phase 3 monotherapy topline readout, now guided for Q1 2027. A positive readout would validate palazestrant as a potential best-in-class oral SERD/CERAN and likely drive a significant re-rating given the stock's current ~$7 price vs. a ~$36.50 mean analyst target. A negative or mixed result would be severely punishing given the company's high cash burn and near-total dependence on this single asset.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $7.27entry
- T+1 · 6d ago +10.59%α +9.27% · $8.04
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Olema Oncology reported Q3 2026 net loss of $73.6M ($0.73 per share) vs. consensus $-0.63, with no revenue. The company highlighted upcoming Phase 3 OPERA-01 top-line data in Q1 2027 and continued enrollment in OPERA-02. Cash position is $413.8M. The wider loss reflects increased R&D spending on late-stage trials.
Key Financial Metrics
Key Facts
- Net loss of $73.6M for Q3 2026 vs. $42.2M in Q3 2025
- EPS of $-0.73 vs. consensus $-0.63 (miss of 15.9%)
- Cash and marketable securities of $413.8M as of Sept 30, 2026
- Phase 3 OPERA-01 top-line data expected Q1 2027
- Phase 3 OPERA-02 enrollment accelerating
- Appointed Jason O'Byrne as CFO
- R&D expenses increased to $67.6M from $40.0M year-over-year
Financial Impact
Net loss widened by $31.4M vs. prior year; cash burn $91.7M in Q3 (from $505.4M at Dec 2025 to $413.8M at Sep 2026)
Risk Factors
- Clinical trial failure risk for palazestrant in Phase 3
- Cash burn rate of ~$92M/quarter implies ~4.5 quarters of runway at current spend
- No revenue or near-term commercialization path
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3399295 |
Track record
20 reports on OLMA
1 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +38.44% at T+60 after the Aug 9, 2026 report. 1 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.29 Now $7.36 +0.96% settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 2/10 Entry $7.56 Now $7.36 −2.65% settles Feb 11
- Nov 10, 20266d ago Press Release Neutral 4/10 Viewing Entry $7.27 Now $7.36 +1.24% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $7.33 Now $7.36 +0.41% settles Feb 4
- Oct 16, 20264w ago SC 13D/A Neutral 2/10 Entry $7.11 Now $7.36 +3.52% settles Jan 14
- Oct 15, 20264w ago 8-K Neutral 2/10 Entry $6.58 Now $7.36 +11.85% settles Jan 13
- Oct 2, 20266w ago Press Release Neutral 2/10 Entry $8.25 Now $7.36 −10.79% settles Dec 30
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 4/10 Entry $10.43 to $7.54 Now $7.36 −29.43% ▼ −27.71% −27.22% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bearish 6/10 Entry $11.94 to $7.35 Now $7.36 +38.36% ▲ +38.44% +36.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers